DESIGN AND EVALUATION OF SELF-NANOEMULSIFYING DRUG DELIVERY SYSTEMS OF MANIDIPINE FOR ENHANCEMENT OF SOLUBILITY by SRIKANTH REDDY S & SURESH G
Vol 12, Issue 9, 2019
Online - 2455-3891 
Print - 0974-2441
DESIGN AND EVALUATION OF SELF-NANOEMULSIFYING DRUG DELIVERY SYSTEMS OF 
MANIDIPINE FOR ENHANCEMENT OF SOLUBILITY
SRIKANTH REDDY S, SURESH G*
ABSTRACT
Objective: The present work is aimed at developing liquid self-nanoemulsifying drug delivery system (liquid-SNEDDS) of manidipine.
Methods: The manidipine SNEDDS is formulated with excipients comprising Capmul MCM as oil phase, Transcutol P as surfactant, and Lutrol L 300 
as cosurfactant. The prepared fifteen formulations of manidipine SNEDDS were performed for emulsification time, percentage transmittance, particle 
size, drug release, in vitro dissolution and stability studies. Ternary phase diagram plotted using Chemix software.
Results: The optimized manidipine liquid SNEDDS formulation (F14) subjected to drug-excipient compatibility studies by Fourier-transform infrared 
spectroscopy and characterized for particle size, zeta potential, scanning electron microscopy, and stability studies. The morphology of manidipine 
SNEDDS indicates spherical shape with uniform particle distribution. The percentage drug release from optimized formulation F14 (98.24±5.14%) 
was higher than that of pure drug (39.17±2.98%). The stability data indicated no noticeable change in drug content, emulsifying properties, drug 
release, and appearance.
Conclusion: Hence, a potential SNEDDS formulation of manidipine developed with enhanced solubility, dissolution rate, and bioavailability.
Keywords: Manidipine, Hypertension, Self-nanoemulsifying drug delivery system, Solubility studies, Capmul MCM.
INTRODUCTION
The Class II to Class IV drugs of biopharmaceutical classification system 
suffering with poor water solubility lead to lower intestinal absorption, 
lower bioavailability. Solubilizing poor water-soluble drugs is a major 
challenge in pharmaceutical research.
Lipid-based drug formulations increase the relative solubility of drugs 
in GI track by enhancing absorption. Self-nanoemulsifying drug delivery 
systems (SNEDDS) lipid-based formulations are most promising 
technology in drug delivery [1-3]. SNEDDS is defined as pre-concentrate 
containing a mixture of drug, surfactants, oil, and cosurfactant. The 
smaller size of SNEDDS improves drug dissolution by increasing area 
for drug release, absorption and by promoting lymphatic transport of 
the drug. SNEDDS formulation is used for increasing the solubility, oral 
bioavailability, and permeability of drug. It also protects the drug from 
hostile environment in GI track and is used for selective GI targeting 
drug delivery [4-8].
They have particle size ranging from nanometers to few microns. Based 
on particle size, they are further classified into SMEDDS and SNEDDS. 
SMEDDS forms microemulsions consisting of oil droplet size ranging 
between 100 and 200 nm. SNEDDS contains the droplets whose size is 
less than 100 nm.
Manidipine is used as an antihypertensive. Manidipine binds to voltage-
dependent calcium channels on smooth muscle cells and dissociates 
them, thus blocking the entrance of extracellular calcium into the cell 
hence preventing this contraction [9,10]. This produces vasodilation 
which decreases blood pressure.
The objective of present research is to design and characterize the liquid 
SNEDDS of manidipine. The ability of SNEDDS to improve dissolution 
rate is evaluated. The formulated SNEDDS was characterized for 




Manidipine is gifted by Aurobindo pharma limited, Hyderabad. Capryol 
PGMC and Acrysol K-150 Oleic acid, Lauroglycol, and Transcutol HP 
are procured from Gattefosse, Mumbai. Labrasol, Tween 20, Acconon, 
Lutrol L 300, Capmul CMC, Labrasol, Acconon and Lutrol L 300 were 
generous gift samples from BASF, Mumbai.
Preparation of manidipine standard stock solution
10 mg of working standard manidipine were transferred into a 10 ml 
volumetric flask and were added 1 ml of phosphate buffer pH 1.2 till 
the mark to obtain a solution of 1000 μg/ml. The solution diluted with 
phosphate buffer to get a solution concentration of 100 μg/ml. From 
this solution, a series of aliquots was prepared for further method 
development.
Solubility studies
The solubility of manidipine in different oils (Acrysol K-150, Oleic acid, 
Capryol PGMC, Capmul MCM, and Labrafil), surfactants (Kolliphor ELP, 
Labrasol, Cremophor EL, Lauroglycol, Transcutol HP, and Tween 20), 
and cosurfactants (propylene glycol, Span 20 PEG 400, Acconon, and 
Lutrol L300) were examined by adding excess amount of manidipine 
(approximately 10 mg) with 2 ml each of the above-mentioned 
components. The drug was transferred to 5-ml glass vial and was mixed 
with individual components thoroughly for 10 min. The vials placed in 
shaker bath at 37±1°C for 72 h to attain homogeneity. The samples were 
further centrifuged 8000 rpm for 20–30 min at 4°C. The supernatant 
removed and the drug concentration determined by ultraviolet (UV) at 
228 nm [11].
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i9.34394
Research Article
Department of Pharmaceutics, Career Point University, Kota, Rajasthan, India. Email: suresh.gande@gmail.com
Received: 04 June 2019, Revised and Accepted: 28 June 2019
289
Asian J Pharm Clin Res, Vol 12, Issue 9, 2019, 288-295
 Reddy and Suresh 
Construction of ternary phase diagrams
The phase diagram constructed base on the solubility of drug in various 
excipients. Various combinations of oil, surfactant, and cosurfactant 
were considered for construction of the same.
Surfactant and cosurfactant (Smix) belonging to group were mixed in 
different weight ratio (1:1, 2:1, and 3:1). The Smix ratios are selected 
with increasing surfactant concentration with respect to increasing 
cosurfactant concentration and vice versa. Various weight ratios of oil 
and Smix ranging from 1:9 to 9:1 (1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 8:2, and 
9:1) were taking glass vials.
Pseudoternary phase diagram plotted by aqueous titration method, each 
sample of oil and Smix titrated with aqueous phase. The results tabulated 
based on transparency and ease of flow of emulsion. A pseudo-three-
component phase diagram constructed to mark the physical state of the 
emulsion with oil on the first axis and surfactant on the second axis and 
cosurfactant on the third axis [12,13].
Measurement of percentage transmittance
The manidipine SNEDDS reconstituted with distilled water. The 
resulting emulsion observed visually for any turbidity. The percentage 
transmittance measured using UV spectrophotometer at 228 nm [14].
Emulsification time
With the use of virtual test method, a predetermined volume of mixture 
(0.2 ml) diluted with 300 ml of water at a temperature of 37°C using a 
magnetic stirrer. The tendency of emulsion formation observed [15].
Development of manidipine SNEDDS formulations
The manidipine SNEDDS formulations prepared using Capmul MCM 
were used as oil phase, and Transcutol P and Lutrol L 300 were used as 
surfactant and cosurfactant (Table 1). Manidipine (10 mg) was added to 
oil into glass vial and heated to 40°C. The oily mixture mixed thoroughly 
with surfactant and cosurfactant. The mixture sonicated for 15 min.
Thermodynamic stability studies
The formulations subjected to freeze cycle (−20°C for 2 days followed 
by 40°C for 2 days). The stable samples centrifuged at 3000 rpm for 
5 min and examined for any phase separation. The formulations with no 
phase separation selected for further investigation [16].
Determination of drug content
Manidipine formulation (0.2ml) equivalent to 10 mg is taken in 
volumetric flask and made to 100 ml with phosphate buffer pH 1.2. 1 ml 
of this solution is taken 10 ml flask made up to 10 ml with buffer. The 
solution is diluted to 10 µg/ml, absorbance measured at λmax 228 nm 
against blank. The amount of drug present in 0.2 ml of formulation 
determined by UV spectrophotometric method and drug concentration 
determined from standard graph.
% Drug content=
Actual amount of drug in SNEDDS
Theoretical amount of drug in SNEDDS
×100
In vitro dissolution studies of manidipine SNEDDS formulations
The dissolution studies were undertaken with paddle method in pH 1.2 
phosphate buffer (900 ml) of various concentrations of manidipine at 
37°C and speed of 50 rpm. The liquid SNEDDS whose weight equivalent 
to 10 mg of manidipine was filled into hard gelatin capsules, and samples 
were withdrawn at different time intervals of 2, 5, 10, 15, 20, 25, 30, 45, and 
60 min and the amount of manidipine analyzed at 228 nm by UV [17,18].
Characterization of manidipine SNEDDS formulation
Drug-excipient compatibility studies
The drug-excipient compatibility checked by Fourier-transform infrared 
spectroscopy (FTIR) method. An FTIR-8400S Spectrophotometer 
(Shimadzu, Japan) with total reflectance (ATR) accessory used to record 
the infrared spectra. Analysis of manidipine and physical mixtures of the 
drug with the excipients carried out with KBr disc. Eight scans recorded 
at a resolution of 4 cm−1 within frequency range of 400–4000 cm−1.
Determination of droplet size
The droplet size of manidipine SNEDDS formulations determined 
by photon correlation spectroscopy (Malvern Instrument UK) that 
measures the size range of 10 to 5000 nm. The formulations placed in 
an electrophoretic cell after dilution [19].
Determination of zeta potential
The zeta potential of the diluted manidipine SNEDDS formulation 
measured using a zeta meter system. The SNEDDS diluted in ratio 
1:2500 (v/v) and mixed constantly. Zeta-potential of the resulting 
emulsion measured using a Zetasizer.
Determination of shape and surface morphology
Shape and surface morphology of manidipine SNEDDS scanned using 
scanning electron microscopy (SEM). The SNEDDS converted to emulsion 
form and placed on metal stubs coated with gold (HITACHI, S-3700N).
Stability studies
The manidipine SNEDDS formulations pilled in gelatine capsules. 
Stability studies conducted at 25°C/60% relative humidity (RH) and 
40°C/75% RH in stability chambers (Thermolab, Mumbai, India). 
Samples at specified conditions withdrawn for 6 months. Drug content 
for each sample was analyzed by UV method [20].
RESULTS AND DISCUSSION
Solubility studies
The manidipine drug solubility is <1 mg/mL. The solubility of 
manidipine tested in oils phases (Acrysol K-150, Oleic acid, Capryol 
PGMC, Capmul MCM, and Labrafil). The maximum solubility observed 
Table 1: Formulation trials of liquid manidipine self‑nanoemulsifying drug delivery system
Smix (Surfactant: 
cosurfactant)




Oil (Capmul MCM) 
(ml)
Smix (Transcutol P: Lutrol L 300)
(ml)
Water
1.1 1:9 F1 10 0.15 1.35 1.1
2:8 F2 10 0.3 1.2 1.25
3:7 F3 10 0.45 1.05 1.4
4:6 F4 10 0.6 0.9 1.55
5:5 F5 10 0.75 0.75 1.7
2:1 7:3 F6 10 0.15 0.45 3.6
8:2 F7 10 1.2 0.3 3.82
9:1 F8 10 1.35 0.15 3.95
1:9 F9 10 0.15 1.35 2.75
2:8 F10 10 0.3 1.2 2.89
3:1 5:5 F11 10 0.75 0.75 4.61
6:4 F12 10 0.9 0.6 4.72
7:3 F13 10 1.05 0.45 4.86
8:2 F14 10 1.2 0.3 4.91
9:1 F15 10 1.35 0.15 5.2
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in Capmul MCM 61.84 mg/ml. This was selected as oil phase for 
manidipine SNEDDS formulations (Table 2 and Fig. 1).
The solubility of the drug checked in various surfactants Kolliphor 
ELP, Labrasol, Cremophor EL, Lauroglycol, Transcutol HP, and Tween 
20 (Table 3 and Fig. 2) and cosurfactants, PEG 400, Acconon, Lutrol 
L300, and Span 20 (Table 4 and Fig. 3). The maximum solubility found 
41.22 mg/ml of Transcutol HP as a surfactant phase and 133.24 mg/ml 
of Lutrol L300 as a cosurfactant phase. These were chosen as surfactant 
and cosurfactant for SNEDDS formulation.
Pseudoternary phase diagram
From the solubility studies, Capmul MCM was chosen as oil, Transcutol 
P as surfactant, and Lutrol L300 as cosurfactant for SNEDDS 
formulation. A ternary phase diagram plotted indicating that increase 
in concentration surfactant and cosurfactant with oil increases 
the self-emulsifying region. Higher efficiency of self-emulsification 
observed with an increase in surfactant concentration (Figs. 4-6).
Visual observation
The tendency of emulsion formation observed tested by visual 
observation method. This was performed by keeping the surfactant and 
cosurfactant ratio (Smix) as 1:1, 2:1, and 3:1 [21]. Ratios 1:9, 2:8, 3:7, 
4:6, and 5:5 of Smix 1:1, 7:3, 8:2, 9:1, 1:9, and 2:8 of Smix 2:1, and 5:5, 6:4, 
7:3, 8:2, and 9:1 of Smix 3:1 exhibited rapid formation of emulsion with 
clear appearance within short time. Based on this data, the ratios for the 
formulation of SNEDDS were selected (Tables 5-7 and Fig. 7).
Fig. 1: Solubility studies of manidipine in oils
Fig. 2: Solubility studies of manidipine in surfactants
Fig. 3: Solubility studies of manidipine in cosurfactants
Fig. 4: Ternary phase diagram of Capmul MCM and Transcutol P 
and Lutrol L300 for 1:1 ratio of Smix
Table 2: Solubility of manidipine in different oils
S. No. Oils Solubility (mg/ml) 
1 Labrafil 40.28
2 Capmul MCM 61.84
3 Capryol PGMC 52.26
4 Oleic acid 10.23
5 Acrysol K 150 45.67
Table 3: Solubility of manidipine in different surfactants
S. No. Surfactants Solubility (mg/ml)
1 Cremophor EL 85.11
2 Lauroglycol 125.25
3 Kolliphor ELP 91.21
4 Labrasol 109.81
5 Transcutol HP 241.22
6 Tween 20 35.22
Table 4: Solubility of manidipine in different cosurfactants
S. No. Cosurfactants Solubility (mg/ml)
1 Propylene glycol 81.24
2 Acconon 75.94
3 Lutrol L300 133.24
4 Propylene glycol 400 90.11
5 Span 20 61.21
Table 5: Visual observation test for Smix 
(surfactant: cosurfactant) ratio 1:1
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SNEDDS of manidipine formulated using Capmul MCM (oil), Transcutol P 
(surfactant) and LutrolL300 (cosurfactant). All the fifteen formulations 
prepared were found to be clear and transparent and their complete 
composition analyzed (Table 1).
Thermodynamic stability studies of manidipine SNEDDS
The stability studies conducted indicated no significant phase 
separation or effect of temperature variation on physical appearance 
of the formulations. No significant change observed visually even 
after centrifugation freeze-thaw cycles. The thermodynamically stable 
formulations were selected for further characterization (Table 8).
% transmittance measurement
The transmittance (%T) measures the clarity and transparency of 
emulsions. Formulation F14 exhibited % transmittance value >99%. 
Transmittance values were <99% suggesting less clarity of emulsions 
(Table 9).
Drug content of manidipine SNEDDS
The drug content of the formulated manidipine SNEDDS found to be in 
the range of 91.19–98.96%. A maximum of 98.96 % was found in the 
formulation F14 (Table 10).
Fig. 5: Ternary phase diagram of Capmul MCM and Transcutol P 
and Lutrol L300 for 2:1 ratio of Smix
Fig. 6: Ternary phase diagram of Capmul MCM and Transcutol P 
and Lutrol L300 for 3:1 ratio of Smix
Fig. 7: Preparation of manidipine self‑nanoemulsifying drug 
delivery system
Table 6: Visual observation test for Smix 
(surfactant: cosurfactant) ratio 2:1










Table 7: Visual observation test for Smix 
(surfactant: cosurfactant) ratio 3:1


















F1 NPS NC NC
F2 NPS NC NC
F3 NPS NC NC
F4 NPS NC NC
F5 NPS NC NC
F6 NPS NC NC
F7 NPS NC NC
F8 NPS NC NC
F9 NPS NC NC
F10 NPS NC NC
F11 NPS NC NC
F12 NPS NC NC
F13 NPS NC NC
F14 NPS NC NC
F15 NPS NC NC
#NPS-No phase separation. ##NC-No change
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F2 Slightly clear 77.07
F3 Slightly clear 78.92
F4 Turbid 76.92
F5 Slightly clear 79.11
F6 Slightly clear 80.21
F7 Transparent 85.04
F8 Transparent 91.77
F9 Slightly clear 84.68
F10 Slightly clear 78.53





Table 10: % drug content for various formulations of 
manidipine self‑nanoemulsifying drug delivery system
















In vitro dissolution studies of manidipine SNEDDS
The drug dissolution studies indicate that the drug release from F14 
is higher than that of other fourteen formulations and the pure drug 
(Figs. 8-10).
Characterization of manidipine SNEDDS
Drug-excipient interactions by FTIR spectroscopy
The FTIR spectra of pure drug manidipine exhibited bands at 
3026.41 cm−1 due to N-H stretch, at 1640 cm−1 for C=O stretching, and at 
1226.77 cm−1 for aromatic amine group C-N stretching. The spectra also 
showed bands at 1288.49 cm−1 for C-N bending. The FTIR spectrum of 
SNEDDS containing manidipine exhibited characteristic bands consistent 
with the molecular structure of manidipine such as bands at 3095.49 cm−1 
for N-H stretch, at 1678.13 cm−1 for C=O stretching, and at 1226.77 cm−1 
for aromatic amine group C-N stretching. The data indicate no interaction 
between the drug and excipients used in the formulation (Figs. 11-13).
Particle size analysis of manidipine SNEDDS
The droplet size and polydispersity values of manidipine are analyzed. 
The particle size of the optimized manidipine SNEDDS formulation 
(F14) was found to be 22.4 nm and Z-average 23.3 nm. The results 
indicate that all the particles were in the nanometer range. The 
polydispersity index of manidipine SNEDDS optimized formulation 
(F14) was 0.313.
PDI determines the uniformity of particle diameter, and hence, it is 
useful to know the size distribution of nanoemulsion, which enhances 
good particle size distribution (Fig. 14).
Zeta potential of manidipine SNEDDS
The zeta potential of the optimized SNEDDS formulation was found to 
be −5.1 mV which complies with the requirement of the zeta potential 
for particle stability (Fig. 15).
SEM for manidipine SNEDDS
SEM evaluated the morphology of SNEDDS formulation. The data 
showed a spherical shape for the optimized SNEDDS (F14) formulation 
with uniform and relatively narrow particle distribution. Spherical 
particles could be uptaken easier than disfigured ones. Therefore, it 
is speculated that the mean particle size that was obtained using the 
laser diffraction method belongs to the agglomerated SNEDDS particles 
(Fig. 16).
Stability studies
The stability of optimized manidipine SNEDDS formulation studied for 
6 months. The formulation was packed in hard gelatin capsules for the 
Fig. 8: Dissolution profiles of manidipine pure drug and 
formulations (F1 to F5)
Fig. 9: Dissolution profiles of manidipine pure drug and 
formulations (F6 to F10)
Fig. 10: Dissolution profiles of manidipine pure drug and 
formulations (F11 to F15)
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Fig. 11: Fourier‑transform infrared spectroscopy spectrum of manidipine pure drug
Fig. 12: Fourier‑transform infrared spectroscopy spectrum of manidipine physical mixture
Fig. 13: Fourier‑transform infrared spectroscopy spectrum of formulation F14 of manidipine self‑nanoemulsifying drug delivery system
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Fig. 14: Particle size analysis of manidipine self‑nanoemulsifying 
drug delivery system formulation F14
Fig. 15: Zeta potential of the manidipine self‑nanoemulsifying 
drug delivery system optimized formulation F14
stability studies. The studies indicated no significant variation in drug 
release and the drug content, physical and emulsifying properties.
CONCLUSION
The present research is aimed at the formulation and characterization 
of manidipine SNEDDS. The solubility studies indicated maximum 
solubility of drug in Capmul MCM (oil), Transcutol HP (Surfactant), 
and Lutrol L300 (cosurfactant). A tertiary phase diagram plotted in 
accordance with solubility studies indicates that self-emulsifying 
region was enhanced with increase in the concentration of surfactant 
and cosurfactant with oil. The visual observation tests indicate that 
the ratios 1:9, 2:8, 3:7, 4:6, and 5:5 of Smix 1:1, 7:3, 8:2, 9:1, 1:9, and 
2:8 of Smix 2:1, and 5:5, 6:4, 7:3, 8:2, and 9:1 of Smix 3:1 showed rapid 
formation of emulsion within a minute having a clear appearance. 
Based on the results, fifteen manidipine liquid SNEDDS formulations 
F1-F15 were prepared and analyzed. The thermodynamic stability 
studies of all formulations indicate no change in visual description of 
samples. The % transmittance study indicates that manidipine liquid 
SNEDDS formulation F14 has a value >99% indicating high clarity of 
emulsion. The drug content of all formulations ranges from 91.99 to 
98.96% with maximum drug content observed in F14 and the maximum 
drug release found in F14. Hence, F14 is chosen as optimized liquid 
SNEDDS formulation of manidipine. Drug-excipient studies through 
FTIR indicated no interaction between manidipine and formulation 
excipients used. The particle size of F14 is 22.4nm, PI 0.313, and 
Zeta potential −5.1 mv. The SEM studies of optimized formulation 
F14 indicated spherical shape with uniform particle distribution. The 
formulation F14 subjected to stability studies for 6 months indicated no 
significant change in drug content, drug release, emulsifying properties, 
and appearance. Hence, a potential liquid SNEDDs formulation of 
manidipine developed with enhanced solubility, dissolution rate, and 
bioavailability.
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